Noncanonical WNT activation in human right ventricular heart failure

Authors: Jonathan J. Edwards, MD[1,2], Jeffrey Brandimarto MS[2], Dong-Qing Hu MD[3], Sunhye Jeong, PhD[2], Nora Yucel, PhD[2], Li Li BS[2], Kenneth C. Bedi Jr., BS[2], Shogo Wada PhD[2], Danielle Murashige, BS[2], Hyun Tae Hwang[3], PhD, Mingming Zhao, MD[3], Kenneth B. Margulies MD[2], Daniel Bernstein MD[3], Sushma Reddy MD[3], Zoltan P. Arany MD PhD[2]

Affiliations

[1]Division of Cardiology (J.J.E.), Children's Hospital of Philadelphia, Philadelphia, PA.

[2]Cardiovascular Institute (J.J.E., J.B., S.J., N.Y., L.L., K.B., S.W., D.B., K.B.M., Z.P.A.), University of Pennsylvania, Perelman School of Medicine, Philadelphia. [3]Division of Cardiology, Lucile Packard Children's Hospital, (D-Q. H, H.T.H., M.Z., D.B., S.R.) Stanford University, Palo Alto, CA.

Short title: Noncanonical WNT in human RV failure

Co-Corresponding Authors:

Zoltan P. Arany

Director, Cardiovascular Metabolism Program

Perelman School of Medicine, University of Pennsylvania, Cardiovascular Institute

3400 Civic Blvd, Philadelphia, PA 19104.

Tel: 215-898-3482

Email: zarany@pennmedicine.upenn.edu

ORCID: 0000-0003-1368-2453

Jonathan J. Edwards

Division of Cardiology

The Children's Hospital of Philadelphia

3401 Civic Center Boulevard, 8NW90 Philadelphia, PA 19104

Tel: 215-590-3548 Fax: 215-590-5825

Email: EdwardsJ6@email.chop.edu

ORCID: 0000-0002-8153-7066

Word Count: 3509 (Main text)

Non-standard Abbreviations:

CST   Cell Signaling Technology

DCM   dilated cardiomyopathy

FLNA   filamin A

ICM   ischemic cardiomyopathy

LVF   left ventricular failure

NF   nonfailing

PAK1   p-21 activated kinase

pRV   preserved right ventricular function

RA   right atrial pressure

RA:PCWP   right atrial to pulmonary capillary wedge pressure ratio

RT-PCR real time polymerase chain reaction

RV   right ventricle

RVF   right ventricular failure

Abstract

A significant barrier to developing therapies to treat right ventricular (RV) remodeling and RV

failure (RVF) has been a lack of understanding for the molecular pathways that are specifically

activated in pathologic human RV remodeling. Since murine models have suggested

involvement of Wnt signaling in pathologic RV remodeling, we used a candidate gene approach

to study differential WNT expression in human RV remodeling using RVs from three groups:

nonfailing donors, explanted dilated and ischemic cardiomyopathy with either preserved RV

function or with RVF. We identified the noncanonical WNT receptor ROR2 as transcriptionally

strongly upregulated in RVF. ROR2 protein expression correlated linearly to mRNA expression

and to worse RV performance using pretransplant hemodynamic assessments. High ROR2

expression in RVF also correlated to expression of the WNT5A/ROR2/Ca^{2+} responsive protease

calpain as well as cleavage of its downstream target FLNA, and FLNA phosphorylation, another

marker of activation downstream of ROR2. Here we demonstrate robust reactivation of a fetal

WNT gene program, specifically its noncanonical arm, in human RVF characterized by activation

of ROR2/calpain mediated cytoskeleton protein cleavage.

Abstract word count: 174

1 Introduction

Right ventricular failure (RVF) is independently predictive of morbidity and mortality in diverse

disease processes including left ventricular failure (LVF), pulmonary hypertension, and

congenital heart disease (Babu-Narayan, Uebing et al., 2012, Piran, Veldtman et al., 2002, van

Wolferen, Marcus et al., 2007). There is a large gap, however, in our understanding and

management of RVF (Voelkel, Quaife et al., 2006). Multiple studies demonstrate that standard

reverse remodeling agents that unequivocally improve survival for LVF, such as ACE inhibitors

and beta-blockers, rarely have impact in RVF, with sometimes even worsened outcomes (Babu-

Narayan et al., 2012, Dos, Pujadas et al., 2013, Doughan, McConnell et al., 2007, Shaddy,

Boucek et al., 2007). Furthermore, markers of left ventricular remodeling poorly predict RV

dysfunction (di Salvo, Yang et al., 2015). Thus, greater understanding of the fundamental

mechanisms that drive RVF, different from LVF, is needed.

Evidence suggests that an RV-specific remodeling transcriptional program contributes to this

disparate clinical behavior of the RV and LV.(Roche & Redington, 2013) We chose to evaluate

WNT-related differential gene expression in human RV remodeling for multiple reasons.

Canonical Wnt signaling regulates cardiomyocyte proliferation during development, and is

critical to second heart field development—which gives rise to the RV—but relatively

dispensable for the first heart field—which gives rise to the LV (Cohen, Wang et al., 2007,

Pahnke, Conant et al., 2016). In parallel, noncanonical Wnt signaling promotes developmental

cardiomyocyte maturation, and knockout of downstream genes including *Scrib, Vangl2,* or *Rac1*

results in second heart field structural anomalies and altered myocardial patterning and

cardiomyocyte cell shape that resemble those seen in pathologic remodeling (Leung, Lu et al., 2014, Li, Hallett et al., 2011, Phillips, Rhee et al., 2007). In murine models of LVF and *in vitro* cardiomyocyte models, aberrant activation of both canonical and non-canonical Wnt signaling has been connected to cardiomyocyte hypertrophy, fibroblast proliferation and activation, activation of cytoskeleton remodeling, and activation of stress pathways (Barandon, Couffinhal et al., 2003, Iyer, Nagarajan et al., 2018, Oerlemans, Goumans et al., 2010, Qu, Zhou et al., 2007, Zuo, Jones et al., 2012). Unbiased transcriptomics analyses of RVF in mice due to pressure or volume-overload have identified *WNT* signaling as a pathway that is specifically altered in the progression from a compensated to decompensated state (Reddy, Zhao et al., 2013, Urashima, Zhao et al., 2008). In humans, a recent study illustrated that higher *WNT5A* serum levels and myocardial expression correlated with worse RV, but not LV, systolic function and with higher likelihood of death or transplant in patients with dilated cardiomyopathy (DCM) (Abraityte, Lunde et al., 2017). Together, these studies have suggested that embryonic or fetal Wnt expression may be reactivated in RV remodeling, akin to the well-established reactivation of fetal programs in LV remodeling. However these and other studies demonstrating aberrant WNT signaling in RV remodeling have been limited to transcriptomics in murine models or were narrowly designed in humans such that the potential clinical role of WNT signaling in adaptive and pathologic remodeling, with associated preserved function (pRV) and RVF, respectively, remains incompletely defined (Abraityte et al., 2017, Gaertner, Schwientek et al., 2012, Reddy et al., 2013, Urashima et al., 2008, Williams, Cavus et al., 2018). Finally, we also focused on WNT signaling because this pathway is dependent on extracellular factors and cell surface

receptors, potentially facilitating prognostic or therapeutic avenues that target WNT signaling

in RV remodeling.

LVF is an ideal human setting in which to characterize the gene expression signature of adaptive

and pathologic RV remodeling for two reasons. LVF is the most common cause of RVF, and LVF

causes a range of RV involvement—from pRV to RVF—reflecting different types of

adaptive/pathologic RV remodeling or different points in time in disease progression (Grandin,

Zamani et al., 2017, Kormos, Teuteberg et al., 2010). In this study, we leverage a large collection

of human RV tissues from explanted DCM and ischemic (ICM) hearts, stratified with either pRV

or RVF, and from nonfailing (NF) hearts from human donors, in order to identify a robust

reactivation of the fetal noncanonical WNT receptor ROR2, upregulation of ROR2/Ca^{2+}

responsive protease calpain, and increased cleavage of calpain-target cytoskeletal proteins

specifically in severe RVF (Morioka, Tanikawa et al., 2009, Nomi, Oishi et al., 2001, O'Connell,

Fiori et al., 2009). We propose this pathway as a potential novel therapeutic target of

pathologic RV remodeling.

Results

<u>Patient characteristics</u>

We collected RV myocardial tissue from patients undergoing clinical heart transplantation for

LVF due to DCM or ICM and separated them according to the presence of pRV or RVF using

preexplant hemodynamic data, as described in the methods. Median time between

hemodynamic data collection and explantation was 28.5 days (interquartile range: 13 − 53

days). In total, we identified 47 DCM-pRV, 26 DCM-RVF, 31 ICM-pRV, and 9 ICM-RVF, representing the largest and most clinically diverse study of human RV differential gene expression in LVF to date.

We identified no clinical confounders between DCM-pRV/DCM-RVF, ICM-pRV/ICM-RVF, and combined pRV/RVF groups (**Table 1** and **Supplemental Table 1**), including no differences in gender, age, ethnicity, body surface area, body weight, heart weight, renal function by glomerular filtration rate, diabetes, use of reverse remodeling agents collectively or individually (ACE inhibitor, angiotensin receptor blocker, or β-blocker), use of other cardioactive medications (digoxin, diuretics, calcium channel blockers, or milrinone), lipid lowering medications, thyroid medications, or pacemakers. Also, ICM-RVF hearts were no more likely to have significant right coronary artery disease ($\geq$ 70% stenosis) or history of prior coronary intervention compared to their ICM-pRV counterparts, indicating that any observed transcriptional changes could not be attributable to dichotomous coronary involvement.

The NF group was similarly well matched across all four cardiomyopathy hemodynamic groups with respect to age, ethnicity, body surface area, and weight, although not for gender (**Supplemental Table 2**). Previous unbiased studies of cardiac DGE have demonstrated few gender-specific differences, and none in WNT-related gene expression, suggesting a low likelihood that gender differences would impact our findings (Inanloo Rahatloo, Liang et al., 2017).

<u>WNT Pathway Candidate Gene Analysis</u>

<u>RNA expression</u>

In total, we assessed the RV myocardial expression of 28 WNT-related genes including ligands,

receptors and co-receptors, inhibitors, and downstream signaling and transcriptional targets

that have been either previously implicated in RV remodeling in murine models of RVF or have

a known interaction based on literature review (**Supplemental Table 3**). First, we assessed

whether these 28 WNT-related genes and two well described heart failure genes—NPPA and

NPPB—exhibited differential expression between NF/pRV/RVF separately for both DCM and

ICM using Kruskal-Wallis to compare log_2fold changes.(Houweling, van Borren et al., 2005)

Most WNT-related genes (**Supplemental Table 4**) and both natriuretic peptides demonstrated

statistically significant differential expression in at least DCM or ICM, with 12 demonstrating

differential expression in both: AXIN2, CREBBP, DAAM2, FZD1, FZD7, NFATC2, NPPA, ROR2,

SFRP1, SFRP3, WISP2, and WNT10B. Of these 12, only five genes were found to be differentially

expressed between pRV and RVF: CREBBP, NFATC2, NPPA, ROR2, and WISP2 (**Table 2, Figure 1**).

To further prioritize these candidate genes, we performed linear regressions comparing RNA

expression to RA:PCWP and found that ROR2 (R^2 = 0.16, p = 3.2 x 10^{-5}), CREBBP (R^2 = 0.03, p =

0.048), and NFATC2 (R^2 = 0.03, p = 0.048) had modest correlations with the RA:PCWP, while

WISP2 did not (R^2 = 0.01, p = 0.14).

<u>Protein expression</u>

To assess whether protein expression would correlate with the observed transcriptional

upregulation of CREBBP, NFATC2, and ROR2 in RVF, we first performed a preliminary analysis

comparing four representative samples from each group representing the hemodynamic

extremes for pRV and RVF and the lowest NPPA expression for NF. In this preliminary analysis,

strong ROR2 protein expression was observed in the DCM-RVF samples with minimal

expression in the other groups (**Supplemental Figure 1**). A similarly dramatic relationship was

not observed for the other targets; we thus prioritized ROR2 for protein expression analysis in

the remaining 123 samples.

ROR2 protein expression in all 143 samples correlated strongly with RNA expression (R^2 = 0.41,

p = 8.1 x10^{-18}). Median and average RVF-to-pRV fold increase in protein expression were 2.0

and 4.5, respectively, (p < 0.05, **Figure 2**). Furthermore, particularly within the RVF group, ROR2

protein expression increased linearly with higher RA:PCWP (R^2 =0.40, p = 3.0 x10^{-5}, **Figure 2**).

Finally, by using the NF ROR2 RNA and protein expression to establish normative ranges, RVF

samples demonstrated a greater than 3-fold odds (95th percentile confidence intervals) of

expressing ROR2 above the 95th percentile compared to pRV (protein: OR 3.07 (1.1 − 8.4), p =

0.03; RNA: OR 3.18 (1.4 − 7.3), p = 0.0071). In summary, ROR2 expression, both RNA and

protein, correlates directly with RVF categorically, and with worse RV hemodynamics.

<u>Impact of ROR2 expression in RVF</u>

ROR2 expression correlates with actin cytoskeletal remodeling pathways

We next explored what functional impact higher ROR2 expression might have in the setting of

RVF by assessing overall expression and phosphorylation of downstream targets, focusing on

cytoskeletal remodeling pathways. Normalized to GAPDH, we found a 1.5 to 2-fold increase in

calpain, full length FLNA, and full length spectrin protein expression in high ROR2 expressing

RVF patients compared to low ROR2 expression (**Figure 3** and **Table 3**, p < 0.05, for all).

Similarly, we identified an almost 6- and 3-fold increase in the calpain cleavage-mediated FLNA

(190 kDa) and spectrin (150 kDa) breakdown products, respectively. Phosphorylation of FLNA

serine-2152 modulates its mechanosensitive interaction with integrin and inhibits calpain-

mediated cleavage, and ROR2 overexpression in HEK293 cells was found to activate one of the

known kinases for this site—p21-activated kinase (PAK1)—through a presumed indirect

phosphorylation.(Chen, Kolahi et al., 2009, Chen & Stracher, 1989, Goh, Ng et al., 2012) We

therefore assessed the relationship of ROR2 expression, FLNA phosphorylation, and

phosphorylated PAK1 expression. In high ROR2 expressing RVF samples, we observed a nearly

8-fold increase in FLNA phosphorylation normalized to total FLNA and a 2-fold increase in

phosphorylated PAK1 normalized to GAPDH (p < 0.05, both). Given these consistent

relationships observed categorically for high and low ROR2 expression, we next assessed

whether expression of these targets correlated linearly or logarithmically with ROR2 expression

(**Figure 3** and **Table 3**). The most statistically significant correlation observed was a logarithmic

increase in phosphorylated PAK1 with increasing ROR2 expression (R^2 = 0.83, p = 1.4 x 10^{-4}). Full

length and phosphorylated FLNA also correlated significantly in a logarithmic relationship with

ROR2 expression (R^2 = 0.67 and 0.62, respectively, p <0.003). Calpain expression correlated

linearly with ROR2 expression (R^2 = 0.66, p = 0.0018). In summary, within the context of RVF,

high ROR2 expression correlates with calpain expression and calpain-mediated cleavage as well

as an increase in total FLNA, FLNA phosphorylation, and total spectrin expression.

Discussion

To date, there are no evidence-supported therapies that target RV remodeling.(Roche & Redington, 2013) Our lack of understanding of the molecular mechanisms that regulate RV remodeling in humans, particularly with respect to adaptive compared to pathologic remodeling, remains a significant barrier towards achieving this goal. Here, we find compelling evidence that non-canonical WNT signaling, and in particular ROR2 signaling, is aberrantly activated in human RVF.

ROR2 is a cell surface receptor tyrosine kinase that transmits noncanonical WNT signaling following binding of its only known ligand—WNT5A—via planar cell polarity, WNT/Ca^{2+}, and stress pathways including JNK/cJUN.(Stricker, Rauschenberger et al., 2017) ROR2 is broadly expressed during embryogenesis, being critical to cardiac, skeletal, and sympathetic nervous system development, but is silent in most healthy postnatal tissue (Morioka et al., 2009, Nomi et al., 2001, Takeuchi, Takeda et al., 2000). Global knockout of Ror1 reveals no apparent defects in the developing mouse, but knockout of Ror2 resulted in ventricular septal defects and knockout of both Ror2 and Ror1 led to conotruncal type congenital heart defects (Nomi et al., 2001). Interestingly, upon our review of their published histology, we noted a significantly noncompacted appearance to the RV and LV myocardium only in the double knockout, which suggests Ror1/2 play a role in myocardial development similar to other noncanonical WNT genes (e.g. disorganized and noncompacted myocardium with loss of *Daam1, Scrib1*, or second heart field-specific loss of *Rac1*) (Leung et al., 2014, Li et al., 2011, Phillips et al., 2007). ROR2 in disease has been largely studied in the context of tumors, where WNT5A/ROR2 signaling leads

to activation of calpain-mediated cleavage, cytoskeletal rearrangement for purposes of migration, and as a hypoxia-inducible factor downstream of *VHL/HIF* signaling with implications in tumor invasiveness and metastasis (O'Connell et al., 2009, Wright & Rathmell, 2010, Yang, Ji et al., 2017). To date, little is known about the role of ROR2 reactivation in cardiac pathology. In a rat left anterior descending ligation myocardial infarction model, increased protein levels of Wnt5a, Ror2, and Vangl2—one if its immediate downstream targets—were observed in the remote vital area (Hagenmueller, Riffel et al., 2014). Using neonatal rat ventricular myocytes (NRVMs), the authors identified phosphorylation of cJun and Jnk as mediators of this activation. Another group found that Wnt5a stimulation of NRVMs caused hypertrophy, cytoskeletal rearrangement, and mPTP opening, but any dependence on Ror2 or other known Wnt5a receptors was not tested (Zhang, Hu et al., 2018). Our results are thus consistent with, and expand on, what few mechanistic data exist on the role of ROR2 in myocardial remodeling, and suggest that ROR2 induction in RVF mechanistically contributes to the pathogenesis of human RVF.

Any role of ROR2 signaling in calpain-mediated cleavage of FLNA or other proteins in cardiac remodeling has not previously been explored. FLNA is a large scaffolding cytoskeletal protein that is involved in broad cellular functions including maintaining cell and tissue structure (e.g. cross-linking actin filaments, binding integrin, maintaining adherens junctions), cell migration, and as a signaling molecule via nuclear translocation of cleaved fragments (Yue, Huhn et al., 2013). Loss of FLNA in humans or mice causes early lethality with diverse and severe developmental defects affecting the heart, lung, neurologic system, and skeleton (Feng, Chen et

al., 2006). Of note, severe RV myocardial noncompaction has been previously reported in a

patient with a *FLNA* G1728C mutation (Zenker, Nahrlich et al., 2006). FLNA has been connected

to ROR2 in cells other than cardiomyocytes. For example, in melanoma cells, ROR2-FLNA

interaction is critical for WNT5A-induced JNK phosphorylation, cytoskeleton remodeling, and

cell migration, and WNT5A-ROR2 binding induces calpain expression and its cleavage of FLNA

leading to increased invasiveness (Nomachi, Nishita et al., 2008, O'Connell et al., 2009).

Importantly, there is also evidence that calpain contributes to pathologic RV remodeling. In an

acute pressure overload-induced rabbit RVF model, direct right coronary artery infusion of the

selective calpain inhibitor MDL-28710 partially rescued RV function and reduced cleavage of the

cytoskeletal protein talin (Ahmad, Lu et al., 2012). Thus, our findings of ROR2 induction and

activation of its downstream pathways, suggest a model (**Supplemental Figure 2**) whereby an

embryonic WNT5a/ROR2 program is reactivated in the setting of RVF, which then promotes

calpain-mediated cleavage of FLNA and likely other targets, ultimately leading to maladaptive

cytoskeletal changes and worsening RVF.

Limitations

There may have been some disease progression or clinical deterioration in the time interval

between tissue collection and hemodynamic assessments for DCM and ICM RV, although if so,

such changes would likely have introduced variability and weakened our differential expression

analyses. It is also possible that changes in gene expression occurred during the period between

heart harvest and tissue freezing, although this process is highly controlled by the Penn Human

Heart Tissue Library with standard operating procedures including assiduous adherence to cold

cardioplegia and snap freezing samples in liquid nitrogen. Our use of rare human-derived tissue allowed us to examine differential expression in a natural setting, but it did limit our ability to mechanistically evaluate the impact of altered ROR2 expression. Thus, further work will be necessary such as testing the response to RV pressure or volume overload in Ror2 gain-of-function and loss-of-function mice.

Conclusions

In this study, using one of the largest and most diverse existing libraries of human heart tissue, we found that WNT signaling is broadly dysregulated in RV remodeling in the setting of ICM and DCM. We found a large reactivation of embryonic ROR2 RNA and protein expression in RVF, which correlated with worse RV hemodynamics, and with activation of a downstream pathway of increased calpain expression and FLNA cleavage. Taken together, the data reveal the robust activation of noncanonical WNT signaling in human RVF, and identify ROR2 as a potential novel RVF therapeutic target that may suppress cytoskeletal remodeling.

Materials and Methods

<u>Data availability</u>

The datasets generated and analyzed for the current study are available upon reasonable request to the corresponding author.

<u>Human samples</u>

Procurement of all RV myocardial tissue was performed using Gift-of-Life and University of Pennsylvania Institutional Review Board (approval 802781) approved protocols with informed consent provided when appropriate as previously described.(Chen, Caporizzo et al., 2018) Samples were retrospectively obtained from the Penn Human Heart Tissue Library collected from May 2005 to April 2018. DCM and ICM hearts were procured at the time of clinical heart transplantation. The RV functional status (pRV vs. RVF) was identified using pretransplant right atrial (RA) pressure and RA to pulmonary capillary wedge pressure ratio (RA:PCWP) as this has ratio is predictive of RVF in the setting of LVF following left ventricular assist device placement in previously published studies.(Grandin et al., 2017, Kormos et al., 2010) Four cardiomyopathy RV hemodynamic patient groups were identified based on RV hemodynamics (Grandin et al., 2017, Kormos et al., 2010):

DCM-RVF and ICM-RVF: RA $\geq$ 9 and RA:PCWP $\geq$ 0.63

DCM-pRV and ICM- pRV: RA $\leq$ 8 and RA:PCWP $\leq$ 0.37.

Exclusion criteria included prior ventricular assist device, retransplantation, incomplete hemodynamics, or insufficient RV tissue for analysis. Potential clinical confounders to differential gene expression were assessed using chi square analysis test for categorical variables and Mann-Whitney U for continuous variables with pairwise deletion for any missing data. Glomerular filtration rate was calculated using the MDRD equation. All reported p values were adjusted using the Benjamini-Hochberg multiple comparison correction method (adjusted $P < 0.05$ for significance).

Disease groups were compared to a NF cohort, selected from unused Gift-of-Life donor hearts

that were deemed unsuitable for transplantation as previously described.(Chen et al., 2018) We

enriched for normal RV function by selecting those with confirmed minimal tricuspid

insufficiency, preserved left ventricular function by ejection fraction ≥ 50%, and preserved renal

function by creatinine ≤ 1.2.

<u>RNA expression</u>

Total RNA was extracted from coded frozen human tissue samples using RNeasy Mini Kit

(Qiagen Hilden, Germany). RNA samples were diluted to 100 ng/uL by DEPC water using Qubit

fluorometer (Thermo Fisher Scientific Waltham, MA). Human cDNA was synthesized using

MultiScribe Reverse Transcriptase[TM] (Thermo Fisher Scientific). Gene expression was quantified

using SYBR Green Master Mix RT-PCR. RT-PCR primers (sequences in **Supplemental Table 3**)

were validated using primer efficiency and melt curve analyses. Log2fold changes were

calculated using the housekeeping genes GAPDH and TBP. Candidate genes were first assessed

for differential expression in both DCM and ICM using Kruskal-Wallis test to compare log2fold

(adjusted $p < 0.05$) between NF/pRV/RVF for both the DCM and ICM cohorts. Genes that were

differentially expressed for both DCM and ICM were assessed for differential expression

between pRV and RVF using Mann Whitney test after combining DCM and ICM groups.

<u>Protein expression</u>

Genes that demonstrated statistically significant differential expression between pRV and RVF

were further assessed using western blot to evaluate differential protein expression. As a

preliminary analysis, four representative samples from each group were selected using the

lowest and highest RA:RPCW ratio for pRV and RVF, respectively, and the lowest NPPA

expression for the NF controls. Protein extraction was performed using NE-PER^{TM} kit

(ThermoFisher Scientific) to separate cytoplasmic and nuclear fractions. Equal amount

cytoplasmic or nuclear protein according to predicted protein location from each sample was

separated by SDS-PAGE. Western blot was performed using monoclonal antibodies to the

following targets: CREBBP (Cell Signaling Technology (CST) Danvers, MA, cat D6C5), NFATC2

(Abcam, Cambridge, UK, cat ab2722), ROR2 (CST cat D3B6F), TBP (Abcam, cat ab51841), HDAC2

(Abcam, cat ab32117), and GAPDH (CST, cat D16H11). Given preliminary results demonstrating

significant upregulation of ROR2, western blots were performed for all remaining samples. In a

subset of RVF samples with either highest (n = 6) or lowest (n = 6) ROR2 expression, we

performed total protein extraction using RIPA to explore activation of downstream pathways.

Western blot was performed using antibodies to filamin A (FLNA, CST cat 4762), serine-2152

phosphorylated FLNA (CST cat 4761), calpain (CST cat 2556), phosphorylated PAK1 (CST cat

2601), and spectrin (Biolegend, San Diego, CA cat D8B7). Secondary anti-mouse (CST cat 7076)

and anti-rabbit (CST cat 7074) were used as indicated. Densitometry was assessed using

SuperSignal^{TM} West Femto enhanced chemiluminescent substrate (ThermoFisher Scientific) and

ImageStudio (LI-COR Biotechnology, Lincoln, Nebraska).

<u>Statistics</u>

All data was analyzed using RStudio version 1.1.463. Data are presented as median

(interquartile range), count (%), or adjusted R^2 for correlations. Pairwise deletion was

performed for any missing clinical data. Statistical significance was determined using Mann Whitney U or Kruskal-Wallis, where appropriate, for continuous variables, and chi square for categorical variables. All reported p values were adjusted using the Benjamini-Hochberg multiple comparison correction method (adjusted $P < 0.05$ for significance).

Acknowledgements

The authors acknowledge all patients and donors who provided tissue without which this study could not have been performed. The authors acknowledge the Gift-of-Life Donor Program Philadelphia, PA who helped provide access to nonfailing tissue from unused donor hearts.

Sources of Funding

This study was supported by grants from NIH and National Heart, Lung, and Blood Institute (NHLBI) 152446 (to Z.PA.), K08 HL127277-01 (to S.R.), and R01 HL105993 (to K.B.M), and Department of Defense W81XWH18-1-0503 (to Z.P.A.) and PR151448 (to DB and SR). JJE was supported by NIH 5T32HL007915, Matthew's Heart of Hope, and Congenital Heart Disease Coalition.

Author contributions

Conceptualization and Design (JJE, KBM, DB, SR, ZPA). Acquisition of data (JJE, JB, LL, DQH, KCB, DM, HTH, MZ). Analysis and interpretation of data (JJE, JB, SJ, NY, SW, SR, ZPA). Writing and editing of manuscript (JJE, SJ, KBM, SR, ZPA).

Conflicts of Interest

The authors attest they are in compliance with human studies committees and animal welfare

regulations of the authors' institutions and Food and Drug Administration guidelines, including

patient consent where appropriate. The authors have no relationships relevant to the content

of this paper to disclose.

The Paper Explained

PROBLEM

Right ventricular failure occurs in multiple cardiac diseases and is an independent predictor of

morbidity and mortality. Currently no medical therapies exist that can treat or prevent right

ventricular failure. A significant barrier to development of such therapies has been the lack of

understanding for the molecular pathways that drive pathologic and adaptive right ventricular

remodeling in humans. However, murine models indicate involvement of dysregulated WNT

signaling in right ventricular failure.

RESULTS

Using a candidate gene approach, we characterized WNT signaling in human right ventricular

remodeling in three populations: nonfailing (n=29), left ventricular failure with preserved right

ventricular function (n=78) and left ventricular failure with right ventricular failure (n=35). We

found that the noncanonical WNT receptor tyrosine kinase ROR2 is transcriptionally strongly

upregulated in right ventricular failure compared to preserved right ventricular function and

non-failing (Benjamini-Hochberg adjusted p<0.05). ROR2 protein expression correlated linearly

to mRNA expression (R^2=0.41, p=8.1x10^{-18}) among all samples, and to worse right ventricular

hemodynamic performance in right ventricular failure using the right atrial to pulmonary

capillary wedge ratio (R^2=0.40, p=$3.0x10^{-5}$). By comparing right ventricular failure tissue with

high or low ROR2 expression, we found that ROR2 expression is strongly associated with

increased expression and activity of the WNT5A/ROR2/Ca^{2+} responsive protease calpain,

cleavage of its target FLNA, and FLNA phosphorylation, another marker of activation

downstream of ROR2. ROR2 protein expression as a continuous variable, correlated strongly to

expression of calpain (R^2=0.25), total FLNA (R^2=0.67), and FLNA phosphorylation (R^2 =0 .62,

p<0.05 for all).

IMPACT

Here we demonstrate robust reactivation of a fetal noncanonical WNT pathway in human right

ventricular failure characterized by ROR2/Calpain mediated protein cleavage. We propose this a

potential therapeutic target, which will require validation in model systems.

References

Abraityte A, Lunde IG, Askevold ET, Michelsen AE, Christensen G, Aukrust P, Yndestad A, Fiane A, Andreassen A, Aakhus S, Dahl CP, Gullestad L, Broch K, Ueland T (2017) Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. *Sci Rep* 7: 3490

Ahmad HA, Lu L, Ye S, Schwartz GG, Greyson CR (2012) Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. *Am J Respir Cell Mol Biol* 47: 379-86

Babu-Narayan SV, Uebing A, Davlouros PA, Kemp M, Davidson S, Dimopoulos K, Bayne S, Pennell DJ, Gibson DG, Flather M, Kilner PJ, Li W, Gatzoulis MA (2012) Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). *Int J Cardiol* 154: 299-305

Barandon L, Couffinhal T, Ezan J, Dufourcq P, Costet P, Alzieu P, Leroux L, Moreau C, Dare D, Duplaa C (2003) Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. *Circulation* 108: 2282-9

Burke MA, Chang S, Wakimoto H, Gorham JM, Conner DA, Christodoulou DC, Parfenov MG, DePalma SR, Eminaga S, Konno T, Seidman JG, Seidman CE (2016) Molecular profiling of dilated cardiomyopathy that progresses to heart failure. *JCI Insight* 1

Chen CY, Caporizzo MA, Bedi K, Vite A, Bogush AI, Robison P, Heffler JG, Salomon AK, Kelly NA, Babu A, Morley MP, Margulies KB, Prosser BL (2018) Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure. *Nat Med* 24: 1225-1233

Chen HS, Kolahi KS, Mofrad MR (2009) Phosphorylation facilitates the integrin binding of filamin

under force. *Biophys J* 97: 3095-104

Chen M, Stracher A (1989) In situ phosphorylation of platelet actin-binding protein by cAMP-

dependent protein kinase stabilizes it against proteolysis by calpain. *J Biol Chem* 264: 14282-9

Cohen ED, Wang Z, Lepore JJ, Lu MM, Taketo MM, Epstein DJ, Morrisey EE (2007) Wnt/beta-

catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through

regulation of FGF signaling. *J Clin Invest* 117: 1794-804

di Salvo TG, Yang KC, Brittain E, Absi T, Maltais S, Hemnes A (2015) Right ventricular myocardial

biomarkers in human heart failure. *J Card Fail* 21: 398-411

Dos L, Pujadas S, Estruch M, Mas A, Ferreira-Gonzalez I, Pijuan A, Serra R, Ordonez-Llanos J,

Subirana M, Pons-Llado G, Marsal JR, Garcia-Dorado D, Casaldaliga J (2013) Eplerenone in

systemic right ventricle: double blind randomized clinical trial. The evedes study. *Int J Cardiol*

168: 5167-73

Doughan AR, McConnell ME, Book WM (2007) Effect of beta blockers (carvedilol or metoprolol

XL) in patients with transposition of great arteries and dysfunction of the systemic right

ventricle. *Am J Cardiol* 99: 704-6

Feng Y, Chen MH, Moskowitz IP, Mendonza AM, Vidali L, Nakamura F, Kwiatkowski DJ, Walsh

CA (2006) Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac

morphogenesis. *Proc Natl Acad Sci U S A* 103: 19836-41

Gaertner A, Schwientek P, Ellinghaus P, Summer H, Golz S, Kassner A, Schulz U, Gummert J,

Milting H (2012) Myocardial transcriptome analysis of human arrhythmogenic right ventricular

cardiomyopathy. *Physiol Genomics* 44: 99-109

Goh KY, Ng NW, Hagen T, Inoue T (2012) p21-activated kinase interacts with Wnt signaling to regulate tissue polarity and gene expression. *Proc Natl Acad Sci U S A* 109: 15853-8

Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF (2013) Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. *Circ Heart Fail* 6: 136-44

Grandin EW, Zamani P, Mazurek JA, Troutman GS, Birati EY, Vorovich E, Chirinos JA, Tedford RJ, Margulies KB, Atluri P, Rame JE (2017) Right ventricular response to pulsatile load is associated with early right heart failure and mortality after left ventricular assist device. *J Heart Lung Transplant* 36: 97-105

Guo CC, Zhang XL, Yang B, Geng J, Peng B, Zheng JH (2014) Decreased expression of Dkk1 and Dkk3 in human clear cell renal cell carcinoma. *Mol Med Rep* 9: 2367-73

Hagenmueller M, Riffel JH, Bernhold E, Fan J, Katus HA, Hardt SE (2014) Dapper-1 is essential for Wnt5a induced cardiomyocyte hypertrophy by regulating the Wnt/PCP pathway. *FEBS Lett* 588: 2230-7

Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J (2014) Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. *Am J Respir Crit Care Med* 189: 325-34

Houweling AC, van Borren MM, Moorman AF, Christoffels VM (2005) Expression and regulation of the atrial natriuretic factor encoding gene Nppa during development and disease. *Cardiovasc Res* 67: 583-93

InanlooRahatloo K, Liang G, Vo D, Ebert A, Nguyen I, Nguyen PK (2017) Sex-based differences in

myocardial gene expression in recently deceased organ donors with no prior cardiovascular

disease. *PLoS One* 12: e0183874

Iyer LM, Nagarajan S, Woelfer M, Schoger E, Khadjeh S, Zafiriou MP, Kari V, Herting J, Pang ST,

Weber T, Rathjens FS, Fischer TH, Toischer K, Hasenfuss G, Noack C, Johnsen SA, Zelarayan LC

(2018) A context-specific cardiac beta-catenin and GATA4 interaction influences TCF7L2

occupancy and remodels chromatin driving disease progression in the adult heart. *Nucleic Acids*

Res 46: 2850-2867

Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, Massey T, Milano CA,

Moazami N, Sundareswaran KS, Farrar DJ, HeartMate IICI (2010) Right ventricular failure in

patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk

factors, and effect on outcomes. *J Thorac Cardiovasc Surg* 139: 1316-24

Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF,

Blankesteijn WM (2011) Blocking of frizzled signaling with a homologous peptide fragment of

wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after

myocardial infarction. *Circulation* 124: 1626-35

Leung C, Lu X, Liu M, Feng Q (2014) Rac1 signaling is critical to cardiomyocyte polarity and

embryonic heart development. *J Am Heart Assoc* 3: e001271

Li D, Hallett MA, Zhu W, Rubart M, Liu Y, Yang Z, Chen H, Haneline LS, Chan RJ, Schwartz RJ,

Field LJ, Atkinson SJ, Shou W (2011) Dishevelled-associated activator of morphogenesis 1

(Daam1) is required for heart morphogenesis. *Development* 138: 303-15

Mazzotta S, Neves C, Bonner RJ, Bernardo AS, Docherty K, Hoppler S (2016) Distinctive Roles of Canonical and Noncanonical Wnt Signaling in Human Embryonic Cardiomyocyte Development. *Stem Cell Reports* 7: 764-776

Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K (2009) Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. *Cancer Sci* 100: 1227-33

Nagy, II, Railo A, Rapila R, Hast T, Sormunen R, Tavi P, Rasanen J, Vainio SJ (2010) Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and beta-catenin expression. *Cardiovasc Res* 85: 100-9

Nomachi A, Nishita M, Inaba D, Enomoto M, Hamasaki M, Minami Y (2008) Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. *J Biol Chem* 283: 27973-81

Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, Kitamura M, Itoh K, Takeuchi S, Takeda K, Akira S, Ikeya M, Takada S, Minami Y (2001) Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. *Mol Cell Biol* 21: 8329-35

Nopparat J, Zhang J, Lu JP, Chen YH, Zheng D, Neufer PD, Fan JM, Hong H, Boykin C, Lu Q (2015) delta-Catenin, a Wnt/beta-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming. *Oncogene* 34: 1542-52

O'Connell MP, Fiori JL, Baugher KM, Indig FE, French AD, Camilli TC, Frank BP, Earley R, Hoek KS,

Hasskamp JH, Elias EG, Taub DD, Bernier M, Weeraratna AT (2009) Wnt5A activates the calpain-

mediated cleavage of filamin A. *J Invest Dermatol* 129: 1782-9

Oerlemans MI, Goumans MJ, van Middelaar B, Clevers H, Doevendans PA, Sluijter JP (2010)

Active Wnt signaling in response to cardiac injury. *Basic Res Cardiol* 105: 631-41

Pahnke A, Conant G, Huyer LD, Zhao Y, Feric N, Radisic M (2016) The role of Wnt regulation in

heart development, cardiac repair and disease: A tissue engineering perspective. *Biochem*

Biophys Res Commun 473: 698-703

Phillips HM, Rhee HJ, Murdoch JN, Hildreth V, Peat JD, Anderson RH, Copp AJ, Chaudhry B,

Henderson DJ (2007) Disruption of planar cell polarity signaling results in congenital heart

defects and cardiomyopathy attributable to early cardiomyocyte disorganization. *Circ Res* 101:

137-45

Piran S, Veldtman G, Siu S, Webb GD, Liu PP (2002) Heart failure and ventricular dysfunction in

patients with single or systemic right ventricles. *Circulation* 105: 1189-94

Qu J, Zhou J, Yi XP, Dong B, Zheng H, Miller LM, Wang X, Schneider MD, Li F (2007) Cardiac-

specific haploinsufficiency of beta-catenin attenuates cardiac hypertrophy but enhances fetal

gene expression in response to aortic constriction. *J Mol Cell Cardiol* 43: 319-26

Reddy S, Zhao M, Hu DQ, Fajardo G, Katznelson E, Punn R, Spin JM, Chan FP, Bernstein D (2013)

Physiologic and molecular characterization of a murine model of right ventricular volume

overload. *Am J Physiol Heart Circ Physiol* 304: H1314-27

Roche SL, Redington AN (2013) Right ventricle: wrong targets? Another blow for

pharmacotherapy in congenital heart diseases. *Circulation* 127: 314-6

Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED,

Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY, Pediatric Carvedilol

Study G (2007) Carvedilol for children and adolescents with heart failure: a randomized

controlled trial. *JAMA* 298: 1171-9

Sprowl-Tanio S, Habowski AN, Pate KT, McQuade MM, Wang K, Edwards RA, Grun F, Lyou Y,

Waterman ML (2016) Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers

sensitivity to 3-bromopyruvate in colon cancer. *Cancer Metab* 4: 20

Stricker S, Rauschenberger V, Schambony A (2017) ROR-Family Receptor Tyrosine Kinases. *Curr*

Top Dev Biol 123: 105-142

Takeuchi S, Takeda K, Oishi I, Nomi M, Ikeya M, Itoh K, Tamura S, Ueda T, Hatta T, Otani H,

Terashima T, Takada S, Yamamura H, Akira S, Minami Y (2000) Mouse Ror2 receptor tyrosine

kinase is required for the heart development and limb formation. *Genes Cells* 5: 71-8

Urashima T, Zhao M, Wagner R, Fajardo G, Farahani S, Quertermous T, Bernstein D (2008)

Molecular and physiological characterization of RV remodeling in a murine model of pulmonary

stenosis. *Am J Physiol Heart Circ Physiol* 295: H1351-H1368

van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD,

Postmus PE, Vonk-Noordegraaf A (2007) Prognostic value of right ventricular mass, volume, and

function in idiopathic pulmonary arterial hypertension. *Eur Heart J* 28: 1250-7

Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS,

Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart L, Blood

Institute Working Group on C, Molecular Mechanisms of Right Heart F (2006) Right ventricular

function and failure: report of a National Heart, Lung, and Blood Institute working group on

cellular and molecular mechanisms of right heart failure. *Circulation* 114: 1883-91

Wang H, Lee Y, Malbon CC (2004) PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling

pathway in development. *Biochem Soc Trans* 32: 792-6

Williams JL, Cavus O, Loccoh EC, Adelman S, Daugherty JC, Smith SA, Canan B, Janssen PML,

Koenig S, Kline CF, Mohler PJ, Bradley EA (2018) Defining the molecular signatures of human

right heart failure. *Life Sci* 196: 118-126

Wright TM, Rathmell WK (2010) Identification of Ror2 as a hypoxia-inducible factor target in

von Hippel-Lindau-associated renal cell carcinoma. *J Biol Chem* 285: 12916-24

Yang CM, Ji S, Li Y, Fu LY, Jiang T, Meng FD (2017) Ror2, a Developmentally Regulated Kinase, Is

Associated With Tumor Growth, Apoptosis, Migration, and Invasion in Renal Cell Carcinoma.

Oncol Res 25: 195-205

Yue J, Huhn S, Shen Z (2013) Complex roles of filamin-A mediated cytoskeleton network in

cancer progression. *Cell Biosci* 3: 7

Zenker M, Nahrlich L, Sticht H, Reis A, Horn D (2006) Genotype-epigenotype-phenotype

correlations in females with frontometaphyseal dysplasia. *Am J Med Genet A* 140: 1069-73

Zhang P, Hu C, Li Y, Wang Y, Gao L, Lu K, Chang G, Li Y, Qin S, Zhang D (2018) Vangl2 is essential

for myocardial remodeling activated by Wnt/JNK signaling. *Exp Cell Res* 365: 33-45

Zuo S, Jones WK, Li H, He Z, Pasha Z, Yang Y, Wang Y, Fan GC, Ashraf M, Xu M (2012) Paracrine

effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury. *Stem Cells Dev* 21:

598-608

Figure 1 Relative RNA expression of WNT-related genes with differential transcription between pRV and RVF as noted in panels A-D.

Figure 2 ROR2 protein expression increases in RVF and correlates with hemodynamics

(A) Dot plot demonstrating ROR2 protein expression among different groups and (B) linear regression comparing ROR2 protein expression

to RA:PCWP.

Figure 3 ROR2 expression correlates with increases in calpain expression and calpain-mediated

cleavage

(A) Western blots comparing expression of downstream targets between high and low ROR2

expressing RVF patients. (B) Logarithmic regressions comparing ROR2 expression to full length,

calpain cleaved, and phosphorylated FLNA.

Table 1

Clinical and demographic characteristics						
	Dilated Cardiomyopathy			Ischemic Cardiomyopathy		
Variables	RVF n = 26	pRV n = 47	Adj p	RVF n = 9	pRV n = 31	Adj p
Age[a]	56.5 (49, 58)	52.0 (44, 60)	0.60	60.0 (56, 62)	61.0 (55, 63)	1.0
Male	50%	72%	0.60	89%	87%	1.0
Ethnicity			1.0			1.0
Caucasian	54%	64%		89%	84%	
African American	38%	30%		0%	13%	
Other	8%	6%		11%	3%	
Heart weight (grams)[a]	471 (380, 549)	465 (421, 545)	0.87	570 (512, 625)	552 (455, 639)	1.0
Weight (kg)[a]	76 (73, 91)	80 (69, 92)	1.0	93 (84, 113)	82 (75, 94)	0.92
Body surface area (m^2)[a]	1.90 (1.8, 2.1)	1.95 (1.8, 2.1)	1.0	2.19 (2.0, 2.4)	1.99 (1.9, 2.2)	0.92
GFR[#]	49.0 (43, 65)	67.3 (55, 82)	0.10	55.4 (42, 56)	53.5 (44, 70)	1.0
Diabetes Mellitus	32%	28%	1.0	56%	39%	1.0

Insulin	15%	15%	1.0	44%	13%	1.0
Thyroid medication	31%	6%	0.14	33%	16%	1.0
Pacer	38%	21%	0.60	11%	6%	1.0
ACE inhibitor	54%	51%	1.0	56%	58%	1.0
ARB	31%	26%	1.0	22%	16%	1.0
β-blocker	81%	94%	0.60	67%	87%	1.0
Any Reverse Remodeling	100%	96%	1.0	100%	94%	1.0
Calcium Channel Blocker	8%	6%	1.0	0%	0%	1.0
Digoxin	50%	47%	1.0	22%	45%	1.0
Diuretic	100%	87%	0.60	78%	90%	1.0
Lipid lowering	42%	49%	1.0	67%	71%	1.0
Milrinone	65%	72%	1.0	86%	71%	1.0
RCA disease	4%	0%	N/A	56%	74%	1.0
Prior CABG	0%	0%	N/A	67%	43%	1.0
Prior Angioplasty	4%	0%	N/A	56%	52%	1.0
Prior Stent	4%	0%	N/A	56%	52%	1.0

Clinical and demographic attributes of cardiomyopathy hemodynamic groups within DCM and

ICM.

[a]Continuous variables presented as median (interquartile range) and p value using two-tailed

Mann-Whitney U test. Categorical variables presented as percent and p value using Chi square

2x2 contingency tables using pairwise deletion for any missing data. All p values are Benjamini-

Hochberg corrected, and none were less than 0.05. Abbreviations: angiotensin converting

1   enzyme inhibitor (ACE inhibitor), angiotensin receptor blocker (ARB), coronary artery bypass

2   grafting (CABG), glomerular filtration rate (GFR), and RCA (right coronary artery disease).

1 **Table 2**

Differential RNA Expression between RVF and pRV		
Gene	RVF/pRV Fold Expression	Adj p
AXIN2	1.30	0.07
CREBBP	**1.64**	**2.63×10^{-4}**
DAAM2	1.15	0.46
FZD1	1.10	0.55
FZD7	1.19	0.46
NFATC2	**1.46**	**0.033**
NPPA	**2.68**	**0.037**
ROR2	**1.57**	**0.010**
SFRP1	0.90	0.31
SFRP3	1.23	0.13
WISP2	**1.42**	**0.039**
WNT10B	1.03	0.55

2 Genes which were differentially expressed in DCM and ICM pRV/RVF compared to NF using

3 Kruskal Wallis were selected for further analysis comparing RVF to pRV expression using

4 Benjamini Hochberg corrected Mann Whitney U test (p <0.05, bolded for significance).

1   **Table 3**

Increased ROR2 Expression Correlates with Calpain-Mediated Cleavage in Right Ventricular Failure					
Target	ROR2 Expression as Continuous Variable			High vs Low ROR2 Expression	
	Relationship	Adjusted R^2	Adj P	Median Fold	Adj P
Spectrin 285 kDa	Logarithmic	0.17	0.10	1.5	0.0087
Spectrin 150 kDa	Logarithmic	0.17	0.10	2.6	0.015
FLNA 280 kDa	**Logarithmic**	**0.67**	**0.0018**	**2.0**	**0.0087**
FLNA 180 kDa	Logarithmic	0.25	0.077	5.7	0.0087
Phospho:Total FLNA	**Logarithmic**	**0.62**	**0.0025**	**7.9**	**0.0087**
Phosphorylated PAK1	**Logarithmic**	**0.83**	**1.4×10^{-4}**	**2.4**	**0.011**
Calpain	**Linear**	**0.66**	**0.0018**	**1.9**	**0.015**

3   Comparative analysis of high (n = 6) vs low (n = 6) ROR2 expressing RVF samples using ROR2 expression categorically (high vs low) or as a

4   continuous variable. As a continuous variable, target expression was assessed using both logarithmic and linear models and the most

5   significant model for each is displayed. In bold are comparisons that were statistically significant in both analyses.